Ipilimumab Study Shows Clinical Activity in Advanced NSCLC

Bristol-Myers Squibb announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
MarketWatch